Most Recent
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
A court has dismissed a lift supplier’s appeal of a decision rejecting its claim of breach of confidence against a rival, including an “entirely unwarranted” attack on solicitors at Allens over the use of documents obtained by “internet-savvy” search techniques.
Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.
A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company's failure to comply with an earlier ruling.
After a seven-year legal battle, a court has upheld the validity of Neurim Pharmaceutical’s patent for insomnia drug Circadin and ruled two generic drug companies infringed the intellectual property.
Global cryptocurrency and gambling website Stake.com is fighting to strike out claims in a lawsuit by Sydney-based online investment platform Stake over a planned Australian launch.
The maker of Mother Energy drinks has failed to convince the High Court that it should weigh in on its long-running intellectual property spat with Vittoria Coffee, which ended in the removal of its 'Motherland' trade mark.
A solar cell patent at the heart of intellectual property litigation brought by South Korean technology giant Hanwha has been found invalid.
Optus has agreed to rebrand products that Boost Tel claimed had infringed on its trade marks, in a settlement of the rivals' intellectual property spat.